

Encapsulation of pharmaceutical proteins in starch microparticles project

Magle Chemoswed joins collaboration with Malmö University on exciting new project.

The project will focus on the use of the Company technology platform as a novel delivery system in conjunction with proteins. Protein-based therapeutics are becoming increasingly popular in medicine. Compared to low molecular drugs, they are more specific, cause fewer side effects and are environmentally friendly. To increase stability of pharmaceutical proteins, they are often formulated in solid state, where due to low water contents many degradation processes slow down. In this project we will use coated amorphous cross-linked starch microparticles as drug delivery vehicles for therapeutic proteins. For more information see: <https://mau.se/forskning/projekt/encapsulation-of-pharmaceutical-proteins-in-starch-microparticles/>

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

We are Magle Chemoswed, a Malmö-based contract development and manufacturing organization (CDMO) that serves companies in the pharmaceutical and medical device industry on a contract basis. We provide comprehensive services from product development through product manufacturing and we pride ourselves in coming up with solutions to complex healthcare challenges. Together with our customers, we take innovations from idea to product. Learn more on www.maglechemoswed.com.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Encapsulation of pharmaceutical proteins in starch microparticles project](#)